Baili Tianheng announced that the company's self-developed first-line treatment plan for PD-L1 positive locally recurrent unresectable or metastatic triple-negative breast cancer was included in the list of breakthrough treatment varieties by the Drug Review Center of the State Drug Administration. It has recently been publicized, and is the first first-line indication breakthrough therapy for Yizekang® related programs. Yizekang® is the world's first and only EGFR×HER3 dual-antibody ADC approved for marketing. Currently, 8 indications have been included in the list of breakthrough treatment varieties, and 1 has been certified as a breakthrough therapy by the US FDA. Investors are advised to pay attention to the risks of uncertainty in drug research and development, such as technology and approval.

Baili Tianheng announced that the company's self-developed first-line treatment plan for PD-L1 positive locally recurrent unresectable or metastatic triple-negative breast cancer was included in the list of breakthrough treatment varieties by the Drug Review Center of the State Drug Administration. It has recently been publicized, and is the first first-line indication breakthrough therapy for Yizekang® related programs. Yizekang® is the world's first and only EGFR×HER3 dual-antibody ADC approved for marketing. Currently, 8 indications have been included in the list of breakthrough treatment varieties, and 1 has been certified as a breakthrough therapy by the US FDA. Investors are advised to pay attention to the risks of uncertainty in drug research and development, such as technology and approval.